Int Ophthalmol (2018) 38:923–931 https://doi.org/10.1007/s10792-017-0536-0 ORIGINAL PAPER Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy . . . T. Barth F. Zeman H. Helbig M.-A. Gamulescu Received: 29 December 2016 / Accepted: 10 April 2017 / Published online: 19 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Keywords Choroidal neovascularization Punctate Purpose To assess the outcome of patients with inner choroidopathy Intravitreal antiangiogenic choroidal neovascularization (CNV) secondary to therapy Anti-VEGF (vascular endothelial growth punctate inner choroidopathy (PIC) receiving intrav- factor) itreal anti-VEGF (vascular endothelial growth factor) injections. Methods Sixteen eyes of 16 patients diagnosed with Introduction CNV secondary to PIC were retrospectively assessed. Punctate inner choroidopathy (PIC) is a rare, idio- Results Eleven women and ﬁve men with a mean age of 35 years (SD 11, range 16–56 years) received pathic chorioretinopathy that usually affects young and healthy myopic women of Caucasian origin [1, 2]. intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1–9) were given It is deﬁned by the occurrence of multifocal small yellowish white lesions of retinal pigment epithelium per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both
International Ophthalmology – Springer Journals
Published: Apr 19, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera